Invitation from James Drinkwater Chairing The 2nd Annual Pharmaceutical Microbiology East Coast Conference


The 2nd Annual Pharmaceutical Microbiology East Coast conference is returning to the Battery Wharf Hotel, Boston, USA on April 10th and 11th, 2019

BOSTON, MA, UNITED STATES , November 30, 2018 /EINPresswire.com/ — The two-day conference will be discussing best practices and techniques to tackle microbial control challenges within the pharmaceutical microbiology industry.

The Chair for the event was recently announced to be James Drinkwater, Chairman at PHSS and Head of Aseptic Processing Technologies & GMP Compliance, Franz Ziel GmbH

James currently holds the position of Chairman for the Pharmaceutical and Healthcare Sciences Society (PHSS) and lead the PHSS Annex 1 focus group from which 100 pages of comments were provided to the EMA during the revision consultation process. Also as part of the UK delegation from UCL: University College London, to provide Jordanian and Saudi Arabia FDA inspectors training on Quality assurance sterile product manufacturing including environmental control and monitoring for aseptic processing, and he is aware of current challenges and knowledge gaps for both the industry in regulators.

Mr Drinkwater says “As conference chair for the 2nd Annual Pharmaceutical Microbiology East Coast event in Boston, it would be my pleasure to invite you to attend this meeting on April 10th and 11th 2019.
Pharmaceutical Microbiology is a constant within all areas of pharmaceutical manufacturing and the field has been undergoing a period of vast change. With advances in rapid microbial methods, changes to regulations, our increasing knowledge of the human microbiome and new testing methods, the implementation of new strategies for contamination control and applying quality risk management (QRM) are challenging us all.

The Pharmaceutical Microbiology East Coast Conference will include presentations from colleagues with expertise in the following emerging disciplines:

• Science and regulation: preparing suitable contamination control strategies and ensuring CGMP compliance. Including a keynote session on considered impact from revision on Annex 1 on a new Aseptic processing Filling line to provide an insight to attendees of preparation for this upcoming major revision in GMP requirements for future projects.
• Rapid microbial methods, both implementation and an industry perspective on process automation
• Quality control considerations in microbial therapies and mycoplasma testing

Please download the brochure from the website for the full list of speakers and 2-day programme.

The 2019 agenda for the event is packed with hot topics, such as revision of Annex 1, contamination control, regulations of endotoxin detection methods and control, environmental monitoring, rapid microbial methods, sterility assurance, mold isolation, risk mitigation for mycoplasma, animal sera and much more.

For the full agenda and speaker line-up, visit the website to download the brochure at:
www.microbiologyeastcoast.com/PR1

Interested in sponsoring, exhibiting or speaking at this event?
Contact Alia Malick, Director, on +44 (0) 20 827 6168 or email amalick@smi-online.co.uk

For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6162 or ssapal@smi-online.co.uk
Pharmaceutical Microbiology East Coast
April, 10 & 11, 2019
Battery Wharf Hotel, Boston, USA
www.microbiologyeastcoast.com/PR1

Follow us @SMiPharm
#SMiPharmaMicroEC

—- END —-

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Simi Sapal
SMi Group
+442078276000
email us here


Source: EIN Presswire

Think Silicon Announces New NEMA® | GUI-Builder to Empower Programmers of IoT, Embedded and Wearable Devices

New version of graphical user interface development tool speeds simple-to-use creation with powerful features

Designed for both amateur and professional developers, these essential tools help to simply design high quality, seamless and interactive GUIs within minutes for embedded, IoT and wearable devices”

— Ulli Mueller, Vice President, Marketing & Business Development

TORONTO, CANADA, November 30, 2018 /EINPresswire.com/ — Think Silicon, a leader in developing ultra-low power graphics IP technology, announced the first free version of NEMA®|GUI-Builder to speed the creation of high-quality GUIs for Embedded, Internet of Things (IoT) and Wearable devices.

Enabling rapid high-end GUI development on low resource hardware in a fraction of time, programmers for any small-display embedded, IoT or wearable device can use the free tool to create smooth and seamless graphics and animation experiences tailored for fast, responsive (touch) screen applications. NEMA®|GUI-Builder comes with the Think Silicon software API NEMA®|GFX and its highly efficient compression technology NEMA®|TSC™, created for use also on SoC platforms (MCU/MPU) with non-Think Silicon GPUs.

For extra value and even more efficiency, NEMA®|GUI-Builder is paired with the NEMA®|GPU and Display Controller product line. Programmers can achieve additional results including 3D rendering matched with unparalleled battery life performance.

“With the updated version of our free software tool, Think Silicon has the ease of use, speed and support for the programmer in mind. Designed for both amateur and professional developers, these essential tools help to simply design high quality, seamless and interactive graphical user interfaces within minutes for embedded, IoT and wearable devices,” said Ulli Mueller, Vice President, Marketing & Business Development of Think Silicon.

NEMA®|GUI-Builder offers programmers and designers the ability to significantly reduce the time of the GUI development by simply enabling drag-n-drop common control and input elements (e.g. buttons, icons, sliders, containers etc.) on the GUI surface benefited by a large set of library Widgets. NEMA®|GUI-Builder automatically produces power and performance optimized C code, with a small memory footprint by utilizing the 3D features of the NEMA®|GPU-Series and their powerful abilities. New features of NEMA®|GUI-Builder include bilinear filtering, simulation window, C code generation, multiple image and color formats, antialiased fonts, and more.

Designers can continue to use their favorite design tools such as Adobe Photoshop by exporting the created files to PNG or SVG file-formats and importing them into NEMA®|GUI-Builder.

Additional features for professional developers are available upon request. Supported platforms include Linux/X11, Microsoft Windows (available soon) and macOS (available soon).

To obtain the free non-commercial NEMA®|GUI-Builder software and more information, please visit: https://think-silicon.com/products/software/nema-gui-builder/

About Think Silicon:
Think Silicon S.A. is a privately held Limited Company located in: Patras/ Greece (HQ), Toronto/ Canada (Business Development & Marketing office), San Jose/CA, USA (Sales office), Cologne, Germany/EMEA region (Sales office), Taipei/TW (Sales office), Tokyo/JP (Sales office). Think Silicon is specialized in developing and licensing high-performance graphics and AI IP technology for ultra-low power and area limited digital mobile, wearable, embedded devices and IoT end-nodes for fabless semiconductor technology customers.

THINK SILICON and NEMA and combinations thereof, are registered trademarks of Think Silicon. Other names are for informational purposes only and may be trademarks of their respective owners.

Georgia Protogeou
Think Silicon S.A
+30 694 425 5268
email us here


Source: EIN Presswire

Integrative Psychotherapist Anita Bains to be Featured on CUTV News Radio

PARKVILLE, MARYLAND, UNITED STATES, November 29, 2018 /EINPresswire.com/ — There are numerous types of therapy practices each with their own distinct modalities.

Integrative psychotherapy is all about finding the right tool to fit an individual’s needs. Anita Bains is an integrative psychotherapist. She’s spent her career looking for the most effective modalities for individuals looking to restore balance to their emotional lives.

“Our culture is habituated to believe there is a magic silver bullet for every problem, but there isn't,” says Anita. “More and more, people are realizing that. With the work that I do, people progress faster to the life they want to live. When they're free of their past unresolved emotional issues, they've got the energy to create a new life.”

In addition to traditional cognitive behavioral talk therapy, Anita also includes a number of innovative techniques and strategies that help people to identify and remove their hidden emotional and thinking blocks that keep them stuck.

“It's always a combination,” says Anita. “I have a lot of tools in my toolbox and I mix and match according to what my clients need, and which tool seems right for me to help them.”

Anita came to psychotherapy through a master’s program in nursing where she specialized in psychiatric nursing.

“I want to help people to feel better instead of just understanding why they feel bad so I focused on mental health,” says Anita. “I'm a psychiatric clinical nurse specialist and my nursing background helps me understand the whole person. I'm focusing not just on the psychological distress, but also on understanding how our physical body influences our emotions. I'm always listening for signs of physical distress because many of our unresolved emotional issues manifest as physical issues.”

Our beliefs, thoughts, and emotions hold an amazing and transformative power all their own. All we have to do is tap into and harness that power to heal ourselves and fulfill our desires. Anita offers an effective, client-centered, integrative and comprehensive approach that combines EFT and other energy psychology techniques with Western therapeutic modalities that include cognitive behavioral, and psychodynamic paradigms. She also teaches mindfulness-based techniques to help promote relaxation, balance energy and restore health.

Recently, Anita became a certified transformational life coach with the Life Mastery Institute in the DreamBuilder process.

“The integrative tools I use are wonderful for clearing blocks and getting past obstacles, but it doesn't directly focus on creating the new life they want to live,” says Anita. “Many of us have a longing for something better. With my coaching and DreamBuilder tools I help people clarify their longing and discontent and create the life they would truly love living.”

CUTV News Radio will feature Anita Bains in an interview with Jim Masters on December 3rd at 2pm EST.

Listen to the show on BlogTalkRadio.

If you have a question for our guest, call (347) 996-3389.

For more information on Anita Bains, visit www.anitabains.com

Lou Ceparano
CUTV News
(631) 850-3314
email us here
Visit us on social media:
Facebook


Source: EIN Presswire

Oncgnostics GmbH Presents New Clinical Data on GynTect® Precision Diagnostics at EUROGIN 2018

Oncgnostics will discuss new clinical data with gynaecological key opinion leaders at EUROGIN 2018

“We have concluded further clinical trials on the performance of GynTect® will present very convincing results at EUROGIN 2018 ”, states Dr. Alfred Hansel, Oncgnostics Chief Executive Officer”

— Dr. Alfred Hansel

SAN FRANCISCO, CA, USA, November 29, 2018 /EINPresswire.com/ — Oncgnostics GmbH presents new clinical data on GynTect® Precision Diagnostics for triage of unclear cervical cancer screening tests.

Oncgnostics GmbH, a Jena/Germany based company, has developed GynTect® for precision detection of cervical cancer. GynTect® was tested and validated in clinical trials on more than 3,000 samples with a remarkable detection score of 100% in all cervical cancer cases. Moreover, GynTect® identifies all relevant pre-cancerous lesions due to its first-of-a-kind prognostic value.

“We have concluded further clinical trials on the performance of GynTect® in comparison to alternative cervical cancer triage approaches. These results are very convincing and we are happy to present them in 5 talks at the EUROGIN 2018 conference in Lisbon next week”, states Dr. Alfred Hansel, Oncgnostics Chief Executive Officer.

Together with CSO Dr. Martina Schmitz and three Oncgnostics R&D specialists for cervical cancer and head-and-neck cancer diagnostics, Oncgnostics will discuss the new clinical data with gynecological key opinion leaders at Oncgnostics booth for precision cancer diagnostics.

Oncgnostics technology has been exclusively licensed out in 2017 to Sinopharm Group for the greater China region.

Biotech Alliances International Inc., a Silicon Valley-based healthcare-focused investment bank, is serving as the lead investment banker to Oncgnostics globalization and partnering strategy. Meetings with Oncgnostics Management Team can be coordinated at EUROGIN 2018 or JPM2019.

About Oncgnostics GmbH

Oncgnostics GmbH, founded in early 2012 as a spin-off from the Jena University women’s hospital, is a molecular diagnostics company specializing in cancer diagnostics. Oncgnostics tests target epigenetic changes, so-called DNA methylations, that typically occur in cancer cells. The patented biomarkers, which are evaluated using a specific algorithm, are the core of the products and provide the basis for the company’s activities.

About Biotech Alliances International Inc.

Biotech Alliances International Inc. is a San Francisco-based investment bank serving life sciences companies, private equity, and venture capital funds. It provides independent financial and strategic advice including corporate finance, mergers & acquisitions, partnering & licensing, and strategic consulting.

Dr. Franck Brinkhaus
Biotech Alliances International Inc
+1 650-868-8511
email us here


Source: EIN Presswire

DK-OPENSCREEN selects grit42’s platform for its compound management and digital laboratory infrastructure

DK-OPENSCREEN + grit42

DK-OPENSCREEN + grit42

DK-OPENSCREEN announced the selection of the digital laboratory infrastructure specialists, grit42, to provide infrastructure and logistics.

After evaluating several compound management service providers, we selected grit42. We found their comprehensive inventory management platform ideal.”

— Director of DK-OPENSCREEN and Professor at DTU, Mads Hartvig Clausen

COPENHAGEN, DENMARK, November 29, 2018 /EINPresswire.com/ — Director of DK-OPENSCREEN and Professor at the Technical University of Denmark (DTU), Mads Hartvig Clausen, states, "After carefully evaluating several compound management service providers, we selected grit42. We found their comprehensive inventory management platform ideal to keep track of our compounds and assays, in an intelligent and user-friendly way. In addition, they also focus on capturing experiment data including metadata, which allows us to combine the compound library information with the in vitro profiling data from the various assays run under the DK-OPENSCREEN umbrella. This fits perfectly with our future ambition of becoming the leading Danish screening hub, linking academic institutions and private organisations within pre-clinical drug discovery."

CEO of grit42, Claus Stie Kallesøe, continues ”After doing anthropological observations in drug discovery labs for almost 20 years, we have developed our platform to provide high quality data across all the different pre-clinical drug discovery phases. One key strength of our platform is the inherent ability to track and combine the experiment data with assay parameters and the experimental roles of these, enabling advanced metadata and structured quality data collection from all sources and steps in the drug discovery process. In addition to this, we're launching a new Logistics App – which can keep track of anything from compounds, to vials, to plates – which will be a central component in supporting DK-OPENSCREEN with the preparation and handling of plates for their customers.“

DK-OPENSCREEN is the national infrastructure for chemical biology. It is constructed as an open-access platform for interdisciplinary research spanning institutions, institutes, industrial organisations and scientific disciplines. Financed by the Ministry of Higher Education and Science and the partners, DK-OPENSCREEN is founded by four Danish universities: the Technical University of Denmark (DTU), the University of Copenhagen (KU), Aalborg University (AAU) and Aarhus University (AU).

Copenhagen-based grit42 focuses on integrating digital laboratory infrastructure with user-friendly day-to-day lab workflows, as well as handling compound and sample logistics, in order to ensure structured quality data across all the different pre-clinical drug discovery phases.

Lasse Goerlitz
grit42
+45 27 58 26 01
email us here


Source: EIN Presswire

Improving diagnosis from the bottom up

Current Testing for Colon Cancer

Current Testing for Colon Cancer

Wesley Baker – CEO ANCON Medical

ANCON Team in Canterbury

Early diagnosis of colon cancer is critical to improving a person’s chances of survival. The 5-year survival for bowel cancer is over 90% if caught early

The NBT device is very versatile. With further development it could be used to screen for diseases such as bowel cancer and later be reassigned to test for a range of other diseases when needed”

— Wesley Baker – CEO of ANCON Medical

CANTERBURY, KENT, UK, November 29, 2018 /EINPresswire.com/ — A report has been published this week assessing progress on cancer care in England over the past 20 years. In collaboration with Professor Sir Mike Richards and published by The Health Foundation [https://www.health.org.uk/publications/unfinished-business], the report sets out recommendations to help close the gap in survival between patients diagnosed with cancer in England and other comparable countries.

Despite persistent ambitions to be the best in Europe and noted in successive cancer strategies, the gap in survival rates has not been closed. For example, a person diagnosed with colon cancer in the UK has a 60% chance of survival after 5 years, compared with 71% for those living in Australia.

Early diagnosis of colon cancer is critical to improving a person’s chances of survival. The 5-year survival for bowel cancer is over 90% if caught early, but less than 10% if diagnosed at stage 4 and this is precisely the kind of disease where advanced disease screening in the form of ANCON Medical’s NBT technology can be life-saving. Non-invasive, simple to use, and affordable, the Nanoparticle Biomarker Tagging (NBT) device can detect the presence of disease by measuring exhaled breath for signs of the disease.

The technology works by detecting breath specific “biomarkers,” which are DNA-protein controlled volatile organic compound (VOC) metabolites specific to diseases.

“The NBT device is very versatile. With further development it could be used to screen for diseases such as bowel cancer and later be reassigned to test for a range of other diseases when needed,” says ANCON Medical’s CEO, Wesley Baker, who is a member of the Royal Society of Medicine. “Lung cancer, scleroderma, cervical cancer, the Flu virus, tuberculosis and chronic obstructive pulmonary disease (COPD) are just some of the diseases where known biomarkers have been discovered, and ANCON’s NBT can improve the speed of diagnosis.”

Despite progress on reducing mortality, improving the chances of survival and the experience of care, for those diagnosed with cancer in England, the proportion at an early stage remained almost static between 2015 and 2017.

The Health Foundation report outlines measures required to close the gap, including radical improvements in the early diagnosis and detection of cancer. Despite recent investment in equipment to treat cancer, the UK has fallen far behind in the availability of diagnostic equipment per person, ranking 35th out of 37 countries for CT scanners, and 31st out of 36 for MRI scanners. There is also a shortage of staff to operate the machinery and report scan results, leading to delays in diagnosis and treatment.

To read more on this report, visit https://www.health.org.uk/news-and-comment/news/radical-rethink-required-to-close-gap-on-cancer-survival.

For more information on ANCON Medical’s NBT technology, visit http://anconmedical.com/nbt-technology/.

Joanna Stephens
ANCON Medical
+44 1227 811705
email us here


Source: EIN Presswire

Cemtek KVB-Enertec Press Release HCN TDL Update

Cemtek KVB-Enertec, a technology leader in Continuous Emissions Monitoring Systems (CEMS) engineered, built, tested, installed and initiated a custom TDL Analyzer for monitoring highly dangerous Hydrogen Cyanide (HCN) gas at a major Chemical Company in Te

Press Release

Performance Update #4

Cemtek KVB-Enertec, Innovative Emissions Monitoring for Compliance and Process Improvement”

— Ty Smith

SANTA ANA, CA, USA, November 28, 2018 /EINPresswire.com/ — Press Release
Performance Update #4 (Performance Report) Major Texas Chemical Company using Cemtek-Unisearch Tunable Diode Laser Analyzer (TDL) to monitor real-time Hydrogen Cyanide (HCN)
Santa Ana, CA, – October 26th, 2018
Cemtek KVB-Enertec, a technology leader in Continuous Emissions Monitoring Systems (CEMS) engineered, built, tested, installed and initiated a custom TDL Analyzer for monitoring highly dangerous Hydrogen Cyanide (HCN) gas at a major Chemical Company in Texas. The proven Cemtek/Unisearch Model 7000 Tunable Diode Laser (TDL) Monitor was coupled with a long path length white cell and configured to measure ppb levels of HCN. The specialty enclosure was engineered with safety purge & lock-outs designed for the safety of workers and the environment.
This design was first tested on site for an eight-month period and operated flawlessly during that time with no maintenance or breakdowns. This was in stark contrast to the sites’ existing Infra-red based analyzer system which required frequent troubleshooting & service; which posed a significant risk to workers that were required to repair and troubleshoot the Infra-red system. The accuracy was also constantly called into question. Cemtek then engineered & built a new system. The new Cemtek/Unisearch System has been in operation for four years, during this time it has 100% availability, required zero maintenance and has proven accuracy. The chemical plants technical staff said they have not had to touch Cemtek/Unisearch analyzer once in four years and that no other instrument they service has given such a high level of accuracy, performance & reliability.
The laser-based analyzer is a marked improvement on existing technologies used to measure HCN and other gasses in harsh or dangerous applications. The simplicity, accuracy, performance and unmatched reliability results in measurable cost savings for this customer and a short payback time.
Cemtek’s Model 7000 Laser Monitor is a continuous emission monitor designed to measure flue gases for both compliance and process monitoring in the most demanding of applications. The TDL utilizes a near infrared (NIR) Tunable Diode Laser Absorption Spectrometer System utilizing a single mode Distributed Feedback Laser (DFB Laser) for unsurpassed accuracy and performance. Since the spectral purity of the Laser is high and the selected absorption feature is unique, measurements can be made free of interferences from any other gas. The measurements are made in‐situ across the Stack (also known as Integrated Path or “IP”) in either a single or dual pass design depending upon the requirements of the application. A Windows-based Software package is available to display the data on either a host laptop PC or the client’s existing Data Acquisition system.
For more information on the Cemtek 7000 TDL monitor, please visit: http://www.cemteks.com
Cemtek KVB-Enertec is a division of Cemtek Group and provides a single source for cost effective engineering, gas monitoring, Data Acquisition systems (DAHS), CEMS design, integration and field services. All phases of Air Monitoring and reporting requirements are provided using our network of highly skilled Field Service Technicians, CEMS Specialists, Engineers and extensive CEMS design experience, measuring NO, NO2, NOX, SO2, CO, CO2, HCl, NH3, THC, H2S, HCN, Hg and many process gasses.
CEMTEK KVB-Enertec, Inc.
TDL Product Specialist
Gary Cacciatore
gcacciatore@cemteks.com
3041 S Orange Ave, Santa Ana, CA, 92707 (714) 904-0767

Ty Smith
Cemtek KVB-Enertec
email us here
+1 714-437-7100


Source: EIN Presswire

Nexien BioPharma and Ivy League University Medical School Collaborate On Pre-Clinical Cannabinoid Studies

Nexien Biopharma will investigate advanced cannabinoid-based formulations for acute treatment of convulsive disorders with an Ivy League Medical School.

Nexien Biopharma (OTCQB:NXEN)

By using our specific parenteral delivery system and advanced formulations, we hope to shorten the timeline for clinically significant treatment efficacy and symptom reduction.”

— Alex Wasyl, Chief Executive Officer of Nexien Biopharma Inc.

DENVER, COLORADO, UNITED STATES, November 28, 2018 /EINPresswire.com/ — Nexien BioPharma And Ivy League University Medical School Collaborate On Pre-Clinical Cannabinoid Studies

Partnership Will Investigate Advanced Parenteral Cannabinoid-Based Formulations For Acute Treatment of Convulsive Disorders.

DENVER, Colo. (November 28, 2018): Nexien BioPharma Inc. (OTC QB: NXEN) (“Nexien” or the “Company”) announced it is initiating a collaboration with the University Medical School (the “Medical School”) to perform pre-clinical studies using advanced parenteral cannabinoid formulations developed by Nexien, known as NX01R1, NX01R2, and NX01R3 (“formulations”). These formulations target the alleviation of symptoms for the acute treatment and intervention of convulsive disorders and convulsive episodes.

Parenteral administration is a route of administration that includes intramuscular injections of the formulations for optimal dosing and bio-availabilty. Parenteral administration excludes oral administration of drug formulations.

Nexien will provide the Medical School’s Neurology Lab with specific formulations, in addition to a comprehensive study design developed by the Company’s scientific team. This pre-clinical research will be first performed in rodents, and will initially investigate the Maximum Tolerable Dose (“MTD”) Pharmacokinetic (“PK”) and Pharmacodynamic (“PD”) profiles of advanced cannabinoid-based parenteral formulations.

In November 2017, Nexien filed a provisional patent application with the United States Patent and Trademark Office (USPTO) relating to the use of cannabinoids to treat convulsive disorders, specifically epilepsy and refractory epilepsy. Refractory epilepsy is a form of epilepsy in which patients typically do not respond to existing available medications and treatment options.

“Nexien is very excited to be working with such a prestigious Medical School. Specifically, we’re working with the Neurology Department which is chaired by a renowned Epileptologist,” said Alex Wasyl, Chief Executive Officer of Nexien.

“A growing body of existing research performed on specific cannabinoids has shown impressive efficacy for treating targeted convulsive disorders, particularly those in which patients do not respond to currently available medications,” he said. “Nexien’s formulations address an intrinsic problem encountered when using cannabinoids to treat these indications. Cannabinoids intrinsically have very low oral bioavailability, and thus have significantly slower absorption into plasma and target tissues. By using our specific parenteral delivery system and advanced formulations, we hope to shorten the timeline for clinically significant treatment efficacy and symptom reduction compared with currently available cannabinoid-based medication for similar indications.”

About Convulsive Disorders & Refractory Epilepsy

A convulsion is a medical condition in which muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body. Because epileptic seizures typically include convulsions, the term convulsion is sometimes used as a synonym for seizure. However, not all epileptic seizures lead to convulsions, and not all convulsions are caused by epileptic seizures.

Refractory epilepsy means that medication options are not bringing a patient’s seizures under control. This condition might often be called by some other names, such as uncontrolled, intractable, or drug-resistant epilepsy. Refractory epilepsy is seen in adults and in children. About 1-in-3 people with epilepsy have what is considered refractory to some degree.

About Nexien BioPharma Inc.

Nexien BioPharma is a US-based pharmaceutical company engaged in the formulation, development and commercialization of cannabinoid-based pharmaceuticals in accordance with U.S. Food and Drug Administration (“FDA”) pre-clinical and clinical pathways, to address a broad range of medical conditions and disorders.

Nexien BioPharma website: www.NEXIENBioPharma.com

Nexien Disclosure Notice: This press release may contain "forward-looking statements, which are deemed to be any statements made by or on behalf of Nexien BioPharma that are not statements of historical facts. These statements reflect current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this release, including the factors set forth in “Risk Factors” in our most recent Form 10-K filed with the Securities and Exchange Commission (SEC) and subsequent filings with the SEC. Readers are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. Nexien BioPharma undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.

Company Contact:
Mark Lubchenco
Director of Investor Relations
Nexien BioPharma Inc.
Tel: 1-303-495-7583
Email: mlubchenco@nexienbiopharma.com

PR Contact:
Drew White
NisonCo PR
Email: drew@nisonco.com

Mark Lubchenco
Nexien BioPharma Inc
303 495 7583
email us here


Source: EIN Presswire

Q BioMed Inc Announces Acquisition of Cancer Pain Drug Metastron™ from GE Healthcare

Incubation to Monetization

Acceleration Biomedical Technologies

Acceleration Biomedical Technologies from Incubation to Monetization

Acceleration Biomedical Technologies from Incubation to Monetization

CEO and Chairman of Q BioMed

CEO and Chairman

Strategic Acquisition Gives Company Ownership of Brand Name Drug and Related Market Approval in 22 Countries in Which Metastron™is Already Registered & Approved

Q BioMed Inc. (OTCQB: QBIO)

NEW YORK , USA, November 28, 2018 /EINPresswire.com/ — Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is pleased to announce that it has entered into agreement to acquire the metastatic skeletal cancer palliation drug, Metastron™, from GE Healthcare.

The agreement gives Q BioMed ownership of the brand, trademarks and market authorizations in 22 countries. In addition, all historical and current sales and distribution data related to those market authorizations will be assigned or transferred to Q BioMed to allow for as seamless a transition as possible in all markets.

Q BioMed CEO Denis Corin said of the deal, “This is a major deal for Q BioMed. Strategically, it affirms our belief in this drug as an effective and underutilized non-opioid therapy for the treatment of debilitating pain associated with skeletal cancer metastases. Importantly, as we enter this market, we will now have access to all information related to Metastron in 22 countries in which the drug is already approved for sale.” Mr. Corin continued, “This gives us a tremendous springboard to accelerate our revenue potential and establishes a formidable barrier to entry as we grow this market. With regards to the market, it is important to note that our focus is not on the short-term horizon, but rather on the long-term strategic initiative as we look 2 and 5 years down the road at expanding the therapeutic scope for the drug.”

The acquisition agreement with GE Healthcare covers the purchase of the radiopharmaceutical drug Metastron™ and all related intellectual property (IP) including, but not limited to the brand, sales and distribution data, patent, trademark and market authorizations for Metastron in 22 countries in exchange for an undisclosed upfront payment, one milestone payment based on sales and a single digit royalty for 15 years. The first commercial sale of Metastron is expected to occur after the successful transfer or assignment of all IP, material sales and distribution data, technical transfer and establishment of manufacturing capabilities to be made by Q BioMed under the appropriate regulatory filings required by the jurisdictions in which Metastron is sold. The complete transfer and establishment of approved manufacturing facilities will take several months with the relevant international health authorities.

Q BioMed looks forward to updating shareholders and all stakeholders as we advance through the transaction and more importantly, we look forward to providing this drug to the thousands of patients around the world who may depend on it well into the future.

Please visit www.QBioMed.com and sign up for regular updates and additional information and see our 8K filed today.

Follow us on Social Media @QBioMed https://twitter.com/QBioMed

About Q BioMed Inc.

Q BioMed, Inc. is a biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support and expansion capital they need to meet their developmental potential so that they can provide products to patients in need.

Please visit www.qbiomed.com and sign up to receive regular updates. Follow us on social media @QBioMed.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: inspection of the proposed third-party manufacturing facility by the FDA or other comments or requests from the FDA in connection with the above mentioned regulatory filing; failure of the proposed third-party manufacturing facility to pass an inspection by the FDA; regulatory risks; risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Denis Corin
Q BioMed Inc.
+1 646-884-7017
email us here
Visit us on social media:
Facebook
Twitter

Q BioMed Provides an Company Update (Must View)


Source: EIN Presswire

MevoFit launches MevoFit Slim & MevoFit Slim + HR – the “Women’s Only” fitness trackers

MevoFit Slim & Slim + HR (Black, Blue & Red)

MevoFit Slim & Slim + HR (Black, Blue & Red)

MevoFit Slim IP 67 Water Resistant Fitness Band

Designed exclusively for today’s women MevoFit Slim & MevoFit Slim + HR bring in the experience of being slim & stylish!

NEW DELHI, INDIA, November 28, 2018 /EINPresswire.com/ — MevoFit, a promising fitness technology start-up, today announced the launch of its exclusive women’s only fitness trackers – MevoFit Slim and MevoFit Slim + HR. As one of its kind product in India with female centric features, these fitness trackers vaunt a premium & slim design, classy curved glass with flawless round edges, a diagonal groove on the strap matching a seamless cut diamond to suit the aesthetics of modern-day women.

The advanced MevoFit Slim series have been ingeniously designed to bring alive the holistic fitness aspirations of a women while complimenting there looks as well. While trackers come in the size of 38×11.8×12.8 mm,there sleek appearance make them a perfect companion to a women’s wrist. MevoFit Slim is IP67 water resistant; has 0.87 inches OLED customizable touch screen with a brilliant display& are available in multiple colors to match the user’s style. Users can also customize the clock faces as per their taste and moods. The multi-day battery life of 7+ days delivers a consistent performance and makes it a reliable tracking partner for women fitness enthusiasts.

The MevoFit Slim comes with a period tracker, ovulation tracker and coach feature for new moms, providing an independent approach to their life even while managing their daily chores. Whereas the period tracker precautions them for their coming days including emotional shift, ovulation tracker helps them plan for their family with an ease, helping them manage their crucial personal decisions without having to suffer.The coach feature for new moms further provides special assignments & tips by the fitness experts – dieticians and trainers to help them get back in shape, with taking care of the nutritional needs as well.

These sleek and stylish trackers are smart in its creation and has inbuilt tracker for steps made, calories burned, distance covered, sleep details and multi sports tracker as well. MevoFit Slim + HR has an inbuilt optical heartbeat sensor which can further trace the user’s pulse with history records.

With our newly launched MevoFit Slim & MevoFit Slim + HR, we aim to bring a new tracking experience to the Indian women who are trendy and demand technology which may help them attain their daily fitness goals. Our slim fitness band will further create a difference in their lives via tracking women specific health essentials, exclusive to women and intended for women, said Ms.Khyati Mahajan, founder of MevoFit.
The MevoFit Slim and the MevoFit Slim+HR fitness trackers are priced at Rs.2990 onwards and Rs. 3490 onwards respectively. They are available at Amazon and Flipkart webstores.

About the company:

MevoFit is a fitness technology start-up of unique apps & web that reward you with merchandise to lose weight and get fit. MevoFit aspires to touch the lifestyle of its users in multiple ways, not just technology but a whole world of fitness incubating services in the physical and non-physical form to shake up and energize the entire fitness ecosystem. In order to make this goal easier MevoFit has developed an all in one health management ecosystem which includes Fitness Apps, Fitness Merchandise, B2B & B2C Service Platforms. Their fitness gear includes Fitness Bands, Gym Bags, Fitness Apparels & Sports Sipper.

Khyati Mahajan
Mevolife Inc.
+91 8826692984
email us here


Source: EIN Presswire